1-(trifluoromethyl)cyclopropane-1-carboxylic acid is a useful trifluoromethylated azetidine building block for the synthesis of various pharmaceutical compounds, such as P38 kinase inhibitors,GPR119 agonists, inhibitors of Hepatitis C virus replication,TRP-M8 receptor ligands and dipeptidyl peptidase-IV inhibitors and VLA-4 integrin antagonists, etc..
Selective reactions of 1,1-cycloalkanedicarboxylic acids with SF4. a route to 1,1-bis(trifluoromethyl)cycloalkanes, 1-fluoroformyl-1-(trifluoromethyl) cycloalkanes and 1-(trifluoromethyl)-1-cycloalkanecarboxylic acids.
New 3-alkylamino-4H-thieno-1,2,4-thiadiazine 1,1-dioxide derivatives activate ATP-sensitive potassium channels of pancreatic beta cells.
Imidazopyridines: A novel class of hNav1.7 channel blockers.
Imidazopyridines as VLA-4 integrin antagonists.
Biarylpyrazolyl oxadiazole as potent, selective, orally bioavailable cannabinoid-1 receptor antagonists for the treatment of obesity.
Oxadiazole-diarylpyrazole 4-carboxamides as cannabinoid CB1 receptor ligands.
Synthesis and structure-activity relationship of 1,2,4-triazole-containing diarylpyrazolyl carboxamide as CB1 cannabinoid receptor-ligand.
Discovery of MK-5046, a potent, selective bombesin receptor subtype-3 agonist for the treatment of obesity.
Optimization of pharmacokinetics through manipulation of physicochemical properties in a series of HCV inhibitors.
Lead optimization of 4,4-biaryl piperidine amides as γ-secretase inhibitors.